A pilot project, involving three harm reduction centres and needle exchange facilities, linked to the hepatitis C network based in Nice (Réseau Hépatite C Ville-Hôpital Côte d’Azur) has sought to increase the diagnosis and treatment of People Who Inject Drugs (PWID).
The Scanvir project that seeks to increase diagnosis and linkage to care of viral hepatitis amongst people who use drugs has been rolled out across many regions in France, such as Nouvelle Aquitaine, Pays de la Loire, and Île de France, after being successfully piloted in the area of Limoges in 2017
As of 1 October, all people who have public health insurance in Germany are entitled to a free one-off test for viral hepatitis B and C as of the age of 35, as part of the general health check-up for those aged 35 and above.
A micro-elimination project to improve screening and linkage to care for people with viral hepatitis C (HCV) in prison settings in Greece, has been run since 2019 by the Hellenic Liver Patients’ Association (Prometheus) in collaboration with the Greek Association for the Study of the Liver.
ALEXANDROS was a community-based programme offering fast-tracked HCV screening and linkage to care for people who inject drugs (PWID) in the Thessaloniki Metropolitan Area.
ARISTOTLE HCV-HIV was a community-based programme aiming to promote HCV and HIV screening among people who inject drugs (PWID) in Athens and linking those infected to care.
A point-of-care (POC) testing pilot to improve hepatitis C virus (HCV) diagnosis and linkage to care in Lombardy, delivered under the supervision of the Lombardy Regional Government.
A Mobile Outreach Programme (MOP) with three vans to provide integrated care for viral hepatitis B (HBV) and C (HCV) among people who use drugs (PWUD). This community very often faces access barriers to prevention, screening and treatment for HCV.
A low threshold harm reduction centre in the historic centre of Lisbon targeting people who inject drugs (PWID) and delivering integrated services for viral hepatitis, HIV, and STIs.
The ‘Right to Health’ pilot project aimed to improve viral hepatitis C prevention, screening, and linkage to care for current or former drug users in Bucharest. The first initiative of its kind in Romania, the project ran between October 2019 and June 2021.
HepBClink is a micro-elimination project to improve diagnosis of viral hepatitis B and C, and provide linkage to care and treatment among Barcelona-based adult migrants from hepatitis-endemic countries.
The autonomous community of the Balearic Islands (Mallorca, Menorca and Ibiza) delivered a micro-elimination project seeking to identify, link to care, and monitor re-infection through a new model of care aimed at people who inject drugs (PWID).
A sustained test and treat strategy to end viral hepatitis C (HCV) in prison settings using a telemedicine tool to ensure follow-up and monitor therapy, supported by a multidisciplinary network of healthcare providers.
The HONEST micro-elimination project was a test and treat strategy to end viral hepatitis C (HCV) among people serving non-custodial sentences and visiting the Jose Hierro Social Integration Center (SIC) as part of their sentence.
Arud is an NGO which, since its beginnings in 1991, has run one of the largest outpatient addiction units in Europe offering integrated care for about 2,500 patients.
Based on a series of interviews with people with hepatitis B and key stakeholders in Australia and in other Asia Pacific region countries, this research investigates the social, political and economic implications of the disease.
The Budi Lukmanto Foundation, an independent foundation with the goal to improve the health of children in Indonesia, cooperates with healthcare professionals and a private laboratory, Bio Medika, to provide immunization against viral hepatitis B.
The Hepatitis Advocacy and Awareness Project (HAAP) is a project aimed at mobilising community-driven interventions for viral hepatitis prevention in Nasarawa State, North Central, Nigeria.
The Mobile InfoHep Centre (MIHC) is a mobile medical clinic that directly links patients to care services and is equipped with the latest diagnostic tools.
Fixpunkt e.V. is a harm reduction service provider established in 1989 in Berlin. Fixpunkt provides large-scale harm reduction services including needle syringe distribution, counselling, a drop-in centre, a drug consumption room and outreach activities.
The HepCheck study sought to investigate the characterization of hepatitis C (HCV) burden among individuals who attended an intensified screening programme for hepatitis C in homeless services in Dublin.
Emergis is a mental health care institution based in the Netherlands that treats over 13,000 people with psychiatric disorders each year.
Prindsen is a low-threshold clinic established in Oslo in 2013 and designed to help people who inject drugs (PWIDs) who are infected with hepatitis C. The clinic provides emergency housing, a needle exchange programme, a health clinic and a drug consumption room.
The Community Screening Network is a project promoted by GAT – Grupo de Ativistas em Tratamentos (Treatment Activist Group) in partnership with the Institute of Public Health at the University of Porto (ISPUP) and AIDS Healthcare Foundation (AHF).
HepaMed is a programme launched in 2018 by the Romanian Ministry for European Funds and co-financed by the 2014-2020 “Capital Uman” Operational Programme. The aim of the programme is to educate healthcare practitioners about prevention and treatment of hepatitis.
The Scottish Hepatitis C Action Plan has been cited as an example of best practice by the WHO, the European Commission and the United Nations Drug Policy Unit.
In Slovenia, the National Strategy for the Management of HCV Infection was developed in 1997 by the multidisciplinary National Viral Hepatitis Expert Board in close cooperation with the Ministry of Health, the National Health Insurance System, and non-governmental organisations.
ASSCAT (Associació Catalana de pacients hepàtics) is a not-for-profit association based in Barcelona that provides information and counselling to hepatitis patients and their families, to make them aware of prevention and treatment.